Welcome to Tenaci-T Therapeutics
Engineering T-Cell Receptors to Precisely Target Solid Tumors
Our T-cell receptors are carefully identified, selected, and validated to destroy tumor cells across lung cancer and other solid tumor types.
Core Technology
Transforming Immunotherapy Through Precision TCR Engineering
Tenaci-T Therapeutics was spun out of Dr. Alexandre Reuben's lab at MD Anderson Cancer Center. Over several years, Dr. Reuben's lab developed a TCR discovery pipeline which has enabled the validation of more than a dozen T cell receptors targeting some of the most prevalent antigens in lung cancer and other solid tumors. Tenaci-T Therapeutics aims to advance these receptors into the clinic.
Target
Discovery
TCR
Optimization
Experimental
Validation
Clinical
Translation
Tenaci-T Therapeutics
What Makes Us Different
Why Our T-Cell Receptor Platform Stands Apart
High prevalence antigens/targets across solid tumors
Diverse HLA restrictions prevalent across patient populations in North America, Europe, and Asia
Different antigen classes including tumor-associated antigens, point mutations, indels, and duplications
Selected antigens are essential to the tumor phenotype, ensuring clonal expression and low intratumor heterogeneity
TCRs selected based on function rather than solely affinity
TCR-T exhibit ability to serially kill multiple targets
Extensive cross-reactivity and safety testing via X-scan and tissue/cell arrays
Antigens selected and TCR-T selected to overcome therapeutic resistance to standard of care
Features
Advancing a Robust Pipeline Toward the Clinic
Early Discovery Candidates
The Early Drug Discovery Process typically starts by screening for potentially active compounds.
Preclinical Programs
Preclinical programs are the stage of drug and medical device development that occurs before human testing,
Target Validation Highlights
Target Validation Highlights" refers to the core concepts and critical methods used in the drug discovery process to confirm that a potential molecular target.
Visual Pipeline Graphic
A visual pipeline graphic is a chart or diagram that represents a sequence of steps .
Who We Are
About Tenaci-T Therapeutics
Our mission is to provide potent and durable therapeutic options to patients with aggressive solid cancers.
We are committed to developing transformative T-cell receptor therapies that provide durable, targeted treatment options for patients with solid tumors.
Meet Our Team
Founder, ATTACHbio
Assistant Professor, MD Anderson
Director, Immunology Program
Chair and Professor
of Thoracic/Head & Neck Medical Oncology, MD Anderson
, Research & Development
Consultant,
Professor & Chair, Dept. Of Neurosurgery, MD Anderson
Consultant
Professor, Department of Cancer Biology, MD Anderson
Pipeline
TCR Pipeline
| Drug ID | Target | HLA | Indications |
|---|---|---|---|
| TTX-1 | TAA | HLA-A*02:01 | Lung Cancer |
| TTX-2 | TAA | HLA-A*03:01 | Lung Cancer |
| TTX-3 | EGFR | HLA-A*11:01 | Lung Cancer |
| TTX-4 | EGFR | HLA-A*03:01 | Lung Cancer |
| TTX-5 | KRAS | HLA-A*11:01 | Lung Cancer, Pancreatic Cancer, Colorectal Cancer |
| TTX-6 | KRAS | HLA-A*02:01 | Lung Cancer, Bladder Cancer, Breast Cancer, Colorectal Cancer |
| TTX-7 | HER2 | HLA-A*03:01 | Lung Cancer, Pancreatic Cancer, Colorectal Cancer |
| TTX-8 | HER2 | HLA-A*11:01 | Lung Cancer, Pancreatic Cancer, Colorectal Cancer |
Tenaci-T Therapeutics
News & Updates
Latest News
Tenaci-T Therapeutics awarded NCI Innovative Concept Award for development of TCR-T immunotherapeutics in glioblastoma multiforme
-Tenaci-T Therapeutics hires Dr.
Jagannadha
Sastry, Ph.D., as Vice President,
Research
& Development
Poster, Publications & Presentations
Explore our library of peer-reviewed posters and scientific presentations showcasing our advancements in T-cell receptor engineering, preclinical validation, and translational research.
